Stock Market News

Horizon Therapeutics downticks as one of three bidders drops out


Horizon Therapeutics (HZNP) downticks as one of three bidders drops out

 

AMGN
+0.18%

Add to/Remove from Watchlist

Add to Watchlist

Add Position

Position added successfully to:

Please name your holdings portfolio

Type:

BUY
SELL

Date:

 

Amount:

Price

Point Value:


Leverage:

1:1
1:10
1:25
1:50
1:100
1:200
1:400
1:500
1:1000

Commission:


 

Create New Watchlist
Create

Create a new holdings portfolio
Add
Create

+ Add another position
Close

JNJ
-0.04%

Add to/Remove from Watchlist

Add to Watchlist

Add Position

Position added successfully to:

Please name your holdings portfolio

Type:

BUY
SELL

Date:

 

Amount:

Price

Point Value:


Leverage:

1:1
1:10
1:25
1:50
1:100
1:200
1:400
1:500
1:1000

Commission:


 

Create New Watchlist
Create

Create a new holdings portfolio
Add
Create

+ Add another position
Close

HZNP
-5.45%

Add to/Remove from Watchlist

Add to Watchlist

Add Position

Position added successfully to:

Please name your holdings portfolio

Type:

BUY
SELL

Date:

 

Amount:

Price

Point Value:


Leverage:

1:1
1:10
1:25
1:50
1:100
1:200
1:400
1:500
1:1000

Commission:


 

Create New Watchlist
Create

Create a new holdings portfolio
Add
Create

+ Add another position
Close

SNY
+0.23%

Add to/Remove from Watchlist

Add to Watchlist

Add Position

Position added successfully to:

Please name your holdings portfolio

Type:

BUY
SELL

Date:

 

Amount:

Price

Point Value:


Leverage:

1:1
1:10
1:25
1:50
1:100
1:200
1:400
1:500
1:1000

Commission:


 

Create New Watchlist
Create

Create a new holdings portfolio
Add
Create

+ Add another position
Close

By Investing.com Staff 

Horizon Therapeutics (NASDAQ:HZNP) fell nearly 5% in early trading Monday after it was disclosed that one of the three original bidders for the company dropped out.

Janssen Global Services, a unit of Johnson & Johnson (NYSE:JNJ), confirmed that it does not intend to make an offer for Horizon.

On November 29th, Horizon announced it was engaged in highly preliminary discussions with Amgen Inc. (NASDAQ:AMGN), Janssen Global Services, LLC, and Sanofi (NASDAQ:SNY).

Both Amgen and Sanofi confirmed late last week they could proceed with all-cash offers for Horizon.

The entire bidding process for Horizon is playing out for the public to witness due to the stringent Irish Takeover Rules, which require both target companies and prospective bidders to disclose information to the public markets at various stages throughout the process.

Despite today’s selling pressure, shares of Horizon are still up 27% since the takeover disclosures in late November. Still, with just two versus three bidders, the auction for the company may be less robust than initially expected.

Several analysts had thought that Horizon could be worth up to $140 per share in a deal. This may need to be dialed back some after today’s news.

Source

Похожие статьи

Добавить комментарий

Ваш адрес email не будет опубликован. Обязательные поля помечены *

Кнопка «Наверх»